Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A

Completed

Conditions studied: Hemophilia A

In brief

This study is to generate qualitative data to evaluate the impact of frequency of FVIII infusions on patients' satisfaction with treatment and their quality of life.

Key facts

Study ID

NCT02971930

Run by

Bayer

People needed

30

Starts

2017-06-20

Expected to finish

2017-12-15

Last updated by the study team

2018-02-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is enrolled in the BAY94-9027 extension studies or is within 3 months of having completed participation in the BAY94-9027 extension studies;
• Patient allocated to Arm 2, Arm 3 or Arm 4 of BAY94-9027 extension studies.
• Arm 2 Prophylaxis treatment of BAY94-9027; 2 infusions per week during the extension study
• Arm 3 Prophylaxis treatment of BAY94-9027; infusion every 5 days during the extension study
• Arm 4 Prophylaxis treatment of BAY94-9027; every 7 days during the extension study
• Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study;
• Patient must be willing and able to participate in a telephone interview lasting up to 30 minutes;
• Patient must have sufficient cognitive and linguistic capacities to allow them to actively participate in an interview lasting 30 minutes.

You may not qualify if…

• Patient is part of Arm 1: On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds;
• Patient is unlikely to comply with the study protocol (e.g. uncooperative attitude) or unlikely to complete the study for any reason in the opinion of the recruiter;
• Patient has great difficulty hearing or reading;
• Patient has any significant comorbid condition (including uncontrolled psychiatric conditions) that might limit or interfere with their ability to talk about their Hemophilia A and participate in the study;
• Patient has severe neurological or cognitive deficits that might affect their ability to participate in an interview.

Where it is running

• Cleveland — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.